Skip to main content
L

LUYAN PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 002788 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,020 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002788

About LUYAN PHARMA CO.,LTD

https://www.luyan.com.cn

Luyan Pharma Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive logistics network, providing supply chain management services to healthcare institutions, including hospitals and community clinics. Its product portfolio encompasses a wide range of Western pharmaceuticals, traditional Chinese medicines, and medical equipment. In addition to wholesale distribution, the company maintains a significant presence in the retail pharmacy sector through a chain of drugstores. Luyan Pharma focuses on optimizing healthcare delivery through integrated distribution systems and value-added services, such as third-party logistics and pharmaceutical cold chain management. The organization leverages its regional market leadership to expand its service footprint and enhance the efficiency of the medical supply chain.

Recent filings

Filing Released Lang Actions
第六届董事会第九次会议决议公告
Regulatory Filings Classification · 1% confidence The document is the public announcement of the resolutions passed at a Board of Directors meeting (the 9th meeting of the 6th board). It outlines board decisions on reports, dividends, auditor reappointments, credit facilities, etc. It is not itself a full financial report, nor an earnings release, nor a shareholder meeting vote result, nor a change in board composition. It is a routine corporate regulatory announcement of board meeting resolutions. No specific category for board meeting resolutions exists, so it falls into the general "Regulatory Filings" fallback (RNS).
2026-04-20 Chinese
独立董事2025年度述职报告（宋培林）
Governance Information Classification · 1% confidence The document is a detailed performance report by the company’s independent director on board and committee attendance, internal controls, audit committee work, governance measures, and regulatory compliance. It is not announcing a change in management (MANG), nor is it a financial results announcement (ER/IR/10-K), nor a proxy or voting result. Instead, it focuses on corporate governance practices, board structure, and oversight activities, matching the Governance Information category (CGR).
2026-04-20 Chinese
鹭燕医药股份有限公司董事会关于独立董事独立性自查情况的专项意见
Governance Information Classification · 1% confidence The document is a board-issued special opinion assessing the independence of the company’s independent directors under exchange rules and corporate governance guidelines. It does not announce board changes (MANG), nor is it an AGM presentation or regulatory notice of a report. It directly addresses governance compliance and board structure requirements. This fits the Governance Information category (CGR).
2026-04-20 Chinese
关于拟续聘2026年度财务审计机构与内部控制审计机构的公告
Regulatory Filings Classification · 1% confidence The document is an announcement by Luyan Pharma regarding the proposed reappointment of its external financial and internal control audit firm for 2026. It does not contain an actual audit report or financial statements, nor is it a management or board change, investor presentation, earnings release, dividend notice, or other specific category. Therefore, it falls into the general regulatory announcement category as a miscellaneous filing.
2026-04-20 Chinese
独立董事2025年度述职报告（叶少琴）
Governance Information Classification · 1% confidence The document is the full text of an independent director’s annual work report (述职报告), detailing attendance at board and committee meetings, review of internal controls, audit committee activities, governance oversight and stakeholder protections. It is not an earnings release, share transaction, proxy solicitation, or a simple announcement; rather it is a substantive governance report by a director on their duties and board governance practices. This most closely fits the Governance Information category (CGR).
2026-04-20 Chinese
2025年年度报告
Annual Report Classification · 1% confidence The document is the '2025 Annual Report' for Luyan Pharma (鹭燕医药股份有限公司). It contains comprehensive financial data, management discussion and analysis, auditor information, and corporate governance details for the fiscal year 2025. It is clearly a full annual report rather than an announcement or summary, as evidenced by the detailed sections (e.g., 'Management Discussion and Analysis', 'Financial Statements', 'Corporate Governance'). FY 2025
2026-04-20 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.